Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill?

International Journal of Artificial Organs

Volumn 33, Issue 3, 2010, Pages 139-146

  Kleger, Gian Reto ^a   Fässler, Edith ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Anticoagulation; Continuous renal replacement therapy; Intensive care medicine; Quality assessment

Indexed keywords

BIOINFORMATICS; PATIENT TREATMENT; QUALITY CONTROL;

ANTI-COAGULATION; CIRCUIT LIFETIME; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILLS; INTENSIVE CARE MEDICINES; QUALITY ASSESSMENT; QUALITY INDICATORS; RENAL REPLACEMENT THERAPIES; SURVIVAL ANALYSIS; VASCULAR ACCESS;

INTENSIVE CARE UNITS;

CITRIC ACID; HEPARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HEALTH CARE QUALITY; HUMAN; INTENSIVE CARE UNIT; MALE; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; VASCULAR ACCESS; AGED; DEVICE FAILURE; DEVICES; HEMODIAFILTRATION; INTENSIVE CARE; KAPLAN MEIER METHOD; MIDDLE AGED; PROSPECTIVE STUDY; TIME;

AGED; ANTICOAGULANTS; CRITICAL CARE; EQUIPMENT FAILURE; HEMODIAFILTRATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY INDICATORS, HEALTH CARE; TIME FACTORS;

EID: 77951096387     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139881003300302     Document Type: Article

References (42)

1. Liano FJ, Pascual E, Madero R, Verde E. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int 1998; 66: S16-24.
2. Uchino SK, Bellomo JA, Doig R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818
3. Metnitz PG, Krenn CG, Steltze H, et al. Effect of acute renal failure recquiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30: 2051-2058
4. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: A worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007; 33: 1563-1570
5. Clark WR, Murphy MH, Alaka KJ, Mueller BA, Pastan SO, Macias WL. Urea kinetics during continuous hemofiltration. ASAIO J 1992; 38: M664-7.
6. Bellomo R, Mansfield D, Rumble S, Shapiro J, Parkin G, Boyce N. A comparison of conventional dialytic therapy and acute continuous hemodiafiltration in the management of acute renal failure in the critically ill. Ren Fail 1993; 15: 595-602. (Pubitemid 23358557)
7. Jones CHR Goutcher D, Newstead E, Will CG, Cohen EJ, Davidson AT, Continuous venovenous high-flux dialysis in multiorgan failure: a 5 year single center experience. Am J Kidney Dis 1998; 31: 227-233
8. Bellomo RR, C. Continuous renal replacement therapy in the intensive care unit. Intensive Care Med 1999; 25: 781-789
9. Misset BT, Chevret JF, Renaud S, Tamion B, Carlet F. A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Care Med 1996; 22: 742-746
10. John SG, Baumgärtel D, Weihprecht M, Schmieder H, Geiger RE. Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: A prospective randomized clinical trial. Nephrol Dial Transplant 2001; 16: 320-327
11. Monti GH, Kindgen-Milles M, Marinho D, Cruz A, Mariano D, Gigliola F, Moretti G, Alessandri E, Robert E, Ronco C. Dose Response Multicentre International Collaborative Initiative Scientific Committee. The DOse REsponse multicentre international collaborative initiative (DO-RE-MI). Contrib Nephrol 2007; 156: 434-443
12. Ronco C, Homel R, Brendolan P, Dan A, Piccini M, La Greca P. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000; 356: 26-30.
13. Saudan PN, De Seigneux M, Romand S, Pugin J, Perneger J, Martin T, P.Y. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 2006; 70: 1312-1317
14. Tolwani AJC, Stofan RC, Lai BS, Oster KR, Wille RA. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008; 19: 1233-1238
15. Network TVNARFT. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20.
16. RENAL Replacement Therapy Study Investigators. Cass BR, Cole A, Finfer L, Gallagher S, Lo M, McArthur S, McGuiness C, Myburgh S, Norton J, Scheinkestel R, Su C. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-1638
17. Vesconi SC, Fumagalli DN, Kindgen-Milles R, Monti D, Marinho G, Mariano A, Formica F, Marchesi M, Robert M, Livigni R, Ronco S, C. for the DOse REsponse Multicentre International collaborative Initiative (DO-RE-MI Study Group). Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care 2009; 13: R57.
18. Uchino SF, Baldwin N, Morimatsu I, Bellomo R. Continuous is not continuous: the incidence and impact of circuit "down time" on uraemic control during during continuous veno-venous haemofiltration. Intensive Care Med 2003; 29: 575-578
19. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359.
20. Mehta RL. Comparing dialysis modalities for critically ill patients: Are we barking up the wrong tree? Clin J Am Soc Nephrol 2007; 2: 413-414
21. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly censored data. Biometrika 1965; 52: 203-223
22. Breslow NE. A generalized Kruskall-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 1970; 57: 579-594
23. Cutts MW, Kishen AN. Transfusion requirements during continuous veno-venous hemofiltration: the importance of filter life. Intensive Care Med 2000; 26: 1694-1697
24. Ward DMM. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993; 4: S237-44.
25. Reeves JHC, Gallagher AR, O'Brien L, Santamaria JL. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-2228
26. Ficcadori EM, Rotelli U, Minari C, Melfa M, Cappè L, Cabassi A. Continuous hemofiltration in acute renal failure with prostacyclin as the sole anti-hemostatic agent. Intensive Care Med 2002; 28: 886-1593
27. Ohtake YH, Sugai H, Oda T, Shiga S, Matsuda H, Kitamura N. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93: 215-217
28. Tan HKB, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high risk patients. Intensive Care Med 2000;26:1652-1657.
29. Palsson RN. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-1997
30. Kutsogiannis DJM, Chin I, Gibney WD. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35: 802-811
31. Monchi M. Citrate versus heparine for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intensive Care Med 2004; 30: 260-265
32. Tolwani AJ. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006; 1: 79-87.
33. Mehta L. Regional citrate anticoagulation for continuous arterio-venous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
34. Tolwani AJ. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60: 370-374
35. Kutsogiannis DJG, Stollery RT, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
36. Gabutti LM, Colucci C, Duchini G, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-1425
37. Donabedian A. An introduction to quality assurance in health care. New York: Oxford University Press; 2003.
38. Schiffl HL, S.M. Fischer, R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346: 305-310
39. Hosmer DW. Applied survival analysis. Regression modeling of time to event data. New York: Wiley; 1999.
40. Le Gall JR. A new simplified acute physiology score (SAPSII) based on an European/North American multicenter study. JAMA 1993; 270: 2957-2963
41. Metnitz PGH. SAPS3-From evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description. Intensive Care Med 2005; 31: 1336-1344
42. Moreno RP. SAPS3-From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005; 31: 1345-1355